Table 4.
Multivariate analysis of prognostic factors for locally advanced NPC
| Endpoint | Variable | Regression coefficient | Standard error | P value | HR | 95% CI |
|---|---|---|---|---|---|---|
| OS | Age (<50 vs. ≥50 years) | 0.793 | 0.251 | 0.002 | 2.209 | 1.350–3.616 |
| T category (T3 vs. T4) | 0.134 | 0.452 | 0.766 | 1.144 | 0.472–2.775 | |
| N category (N0 vs. N1 vs. N2 vs. N3) | 0.364 | 0.133 | 0.006 | 1.439 | 1.108–1.868 | |
| Sex (male vs. female) | −0.168 | 0.278 | 0.547 | 0.845 | 0.490–1.459 | |
| Pathologic type (WHO I vs. II–III) | 0.415 | 0.473 | 0.380 | 1.515 | 0.599–3.830 | |
| Chemotherapy (yes vs. no) | −0.409 | 0.484 | 0.398 | 0.664 | 0.257–1.716 | |
| Radiation dose (<73.92 vs. ≥73.92 Gy) | −0.189 | 0.437 | 0.666 | 0.828 | 0.352–1.950 | |
| GTV-P (≤46.4 vs. >46.4 mL) | 0.901 | 0.261 | 0.001 | 2.463 | 1.478–4.104 | |
| LRFS | Age (<50 vs. ≥50 years) | 1.768 | 0.578 | 0.002 | 5.857 | 1.887–18.186 |
| T category (T3 vs. T4) | −0.151 | 0.801 | 0.851 | 0.86 | 0.179–4.133 | |
| N category (N0 vs. N1 vs. N2 vs. N3) | −0.108 | 0.249 | 0.663 | 0.897 | 0.551–1.462 | |
| Sex (male vs. female) | 0.150 | 0.571 | 0.793 | 1.162 | 0.379–3.557 | |
| Pathologic type (WHO I vs. II-III) | 0.355 | 0.765 | 0.643 | 1.426 | 0.318–6.391 | |
| Chemotherapy (yes vs. no) | −0.369 | 0.776 | 0.634 | 0.691 | 0.151–3.165 | |
| Radiation dose (<73.92 vs. ≥73.92 Gy) | −0.659 | 1.038 | 0.525 | 0.517 | 0.068–3.956 | |
| GTV-P (≤46.4 vs. >46.4 mL) | 1.029 | 0.520 | 0.048 | 2.798 | 1.010–7.746 | |
| DMFS | Age (< 50 vs. ≥ 50 years) | 0.252 | 0.281 | 0.370 | 1.287 | 0.741–2.234 |
| T category (T3 vs. T4) | 0.559 | 0.543 | 0.303 | 1.749 | 0.604–5.068 | |
| N category (N0 vs. N1 vs. N2 vs. N3) | 0.418 | 0.147 | 0.005 | 1.519 | 1.138–2.027 | |
| Sex (male vs. female) | −0.132 | 0.303 | 0.664 | 0.877 | 0.485–1.586 | |
| Pathologic type (WHO I vs. II-III) | 0.255 | 0.525 | 0.627 | 1.291 | 0.461–3.611 | |
| Chemotherapy (yes vs. no) | −0.178 | 0.613 | 0.771 | 0.837 | 0.252–2.780 | |
| Radiation dose (<73.92 vs. ≥73.92 Gy) | −0.024 | 0.440 | 0.956 | 0.976 | 0.412–2.313 | |
| GTV-P (≤46.4 vs. >46.4 mL) | 0.963 | 0.280 | 0.001 | 2.620 | 1.514–4.534 | |
| DFS | Age (<50 vs. ≥50 years) | 0.535 | 0.225 | 0.018 | 1.708 | 1.098–2.656 |
| T category (T3 vs. T4) | 0.376 | 0.415 | 0.365 | 1.457 | 0.646–3.286 | |
| N category (N0 vs. N1 vs. N2 vs. N3) | 0.287 | 0.118 | 0.015 | 1.333 | 1.057–1.680 | |
| Sex (male vs. female) | −0.114 | 0.251 | 0.649 | 0.892 | 0.545–1.459 | |
| Pathological type (WHO I vs. II-III) | 0.423 | 0.401 | 0.292 | 1.526 | 0.695–3.350 | |
| Chemotherapy (yes vs. no) | −0.337 | 0.441 | 0.445 | 0.714 | 0.301–1.694 | |
| Radiation dose (< 73.92 vs. ≥ 73.92 Gy) | −0.105 | 0.379 | 0.781 | 0.900 | 0.428–1.891 | |
| GTV-P (≤ 46.4 vs. > 46.4 mL) | 0.848 | 0.230 | <0.001 | 2.335 | 1.487–3.667 |
HR hazard ratio, CI confidence interval, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
P values were calculated using an adjusted Cox proportional hazards model